Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Type of Laboratory Areas of Activity
External Collaborations
Rentschler Biopharma SE
A world-class biopharmaceutical CDMO
›
Erwin-Rentschler-Str. 21 88471 Laupheim Germany Dr Cora Kaiser (Senior Director Corporate Communication) +49-7392-701-0 +49-7392-701-300 communications@ rentschler-biopharma.com www.rentschler-biopharma.com
Rentschler Biopharma is a leading global contract development and manufacturing organisation (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany, and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals. The company’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. Rentschler Biopharma is a familyowned company with about 1,100 employees. In Stevenage, UK, Rentschler Biopharma launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.
›
FIQ
›
› › › ›
› › ›
› › ›
›
›
1,100 1927 S1 | Contract development and manufacturing organization (CDMO) for biopharmaceuticals | Cell and Gene Therapy Services with Rentschler ATMP Ltd Strategic alliance with Leukocare AG, located in Munich, Germany, for bestin-class formulations Strategic collaboration with Vetter, headquartered in Ravensburg, Germany, for high quality aseptic filling and secondary packaging
Request for Further Collaborations
›
Rentschler Biopharma offers bioprocess development and cGMP manufacturing solutions from concept to market for pharma and biotech companies in long-term collaborations and strategic collaboration settings.
Your trusted partner from concept to market Rentschler Biopharma’s end-to-end offering includes biopharmaceutical process development and manufacturing as well as related consulting activities such as project management and regulator y suppor t. Rentschler Biopharma is highly experienced in the development and cGMP manufacturing of monoclonal antibodies, designer proteins, and other therapeutic proteins in compliance with international standards (EMA/FDA). Since 2020, the company has expanded into the promising field of mRNA production. Working collaboratively with its clients, Rentschler Biopharma provides customised solutions with optimised work packages for each development stage. State-of-the-art cGMP facilities and cell culture processes are leveraged for manufacturing for both, clinical studies and commercial supply. Consistent monitoring of the international regulatory landscape and in-depth understanding of the necessary regulatory documentation (CMC), ensures that each project is properly documented in accordance with international regulatory requirements. In order to offer value-adding solutions across the entire process chain, the company has entered into a strategic alliance with Leukocare for formulation development. Another strategic collaboration is with Vetter for aseptic manufacturing and packaging. The desired goal of the collaboration with Vetter is the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
